[1] Glezer A, Bronstein MD. Prolactinomas. Endocrinol Metab Clin North Am, 2014; 44, 71-8. doi:  10.1007/978-1-59259-217-3_16
[2] Han WD, Mu YM, Lu XC, et al. Up-regulation of LRP16 mRNA by 17β-estradiol through activation of estrogen receptor (ERα), but not ERβ, and promotion of human breast cancer MCF-7 cell proliferation: a preliminary report. Endocr Relat Cancer, 2003; 10, 217-24. doi:  10.1677/erc.0.0100217
[3] Meng YG, Han WD, Zhao YL, et al. Induction of the LRP16 gene by estrogen promotes the invasive growth of Ishikawa human endometrial cancer cells through the down-regulation of E-cadherin. Cell Research, 2007; 17, 869-80. doi:  10.1038/cr.2007.79
[4] Sanjay Kansra, Sayaka Yamagata, Leighton Sneade, et al. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol, 2005; 239, 27-36. doi:  10.1016/j.mce.2005.04.008
[5] Han WD, Si YL, Zhao YL, et al. GC-rich promoter elements maximally confers estrogen-induced transactivation of LRP16 gene through ER alpha/Sp1 interaction in MCF-7 cells. J Steroid Biochem Mol Biol, 2008; 109, 47-56. doi:  10.1016/j.jsbmb.2007.12.009
[6] Aekkapot Chamkasem, Waraphan Toniti. Sequence to Structure Approach of Estrogen Receptor Alpha and Ligand Interactions. Asian Pac J Cancer Prev, 2015; 16, 2161-6. doi:  10.7314/APJCP.2015.16.6.2161
[7] Susumu Takekoshi, Yuzo Yasu, Chie Inomoto, et al. A Histopathological Study of Multi-hormone Producing Proliferative Lesions in Estrogen-induced Rat Pituitary Prolactinoma. Acta Histochem Cytochem, 2014; 47, 155-64. doi:  10.1267/ahc.14029